Loading
Dapagliflozin / Cardiorenal Syndrome · Phase 2 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 feasibility study of dapagliflozin in acute cardiorenal syndrome that has completed recruitment of 30 participants. The study measures feasibility and acceptability (enrollment rate, consent rate, sample completion) as a precursor to a future randomized clinical trial; no clinical outcomes are reported in this registry record.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Cardiorenal Syndrome; age from 18 Years; to 85 Years. Intervention: SGLT2i administration. Compared with: Usual Care — No Intervention. n = 30. 1 site: United States.
Enrollment status: COMPLETED with 30 participants actually enrolled Primary endpoints are feasibility measures: percentage of eligible versus consented patients, percentage with completed sample collections, and enrollment rate Study duration approximately 2 years from initiation to close
Feasibility endpoints do not assess efficacy, safety, or clinical benefit of dapagliflozin
This feasibility study does not provide evidence of clinical benefit or harm. Results, if reported separately, would inform the design and feasibility of a future definitive randomized trial testing whether SGLT2 inhibitors improve symptomatic recovery and kidney function in this population.
A Phase 2 feasibility study with recruitment completed but no clinical outcome results reported; designed to assess trial feasibility and acceptability rather than efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This feasibility study does not provide evidence of clinical benefit or harm. Results, if reported separately, would inform the design and feasibility of a future definitive randomized trial testing whether SGLT2 inhibitors improve symptomatic recovery and kidney function in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Registry record from ClinicalTrials.gov (NCT06111768). This is a study registration, not published results. Lead sponsor: Yale University. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 30 participants (ACTUAL). Conditions: Cardiorenal Syndrome. Interventions: DRUG: Dapagliflozin. Primary outcome measures: Percentage of eligible versus consented patients , From study initiation to study close (about 2 years); Percentage of enrolled patients with completed sample collections , From study initiation to study close (about 2 years); Enrollment rate , From study initiation to study close (about 2 years). Brief summary: The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.